Signant Health announced that it will connect its TrialMax electronic clinical outcome assessment (eCOA) platform to Propeller Health’s inhaler sensor and linked digital health platform. The combined platform will be aimed towards patients living with asthma and chronic obstructive pulmonary disease (COPD).
According to Signant Health, the linked platforms will lead to better patient adherence to inhaled medications by allowing clients to track medication usage.
The offering is targeted at clinical trial sponsors, clinical research organizations (CROs), and academic institutions.
The ability to follow when patients are using an inhaler would allow those connected to the database to determine when symptoms are triggered, as well as how patients are following their treatment plan.
In addition, it could allow researchers to determine how patients’ use of medication relates to their response to treatment, the company stated.
In a previous interview with Outsourcing-Pharma, Mike Nolte, CEO of Signant Health, told us how its eCOA platform is beneficial for its clients: “The more we can create enhanced visibility for customers to make good investments and decisions and help them measure the experience in the conduct of research, reversing the lens to view this from a patient perspective, the more we see an untapped area to do exciting new things.”
Bill Byrom, the company’s VP of product strategy and innovation, explained that the Propeller’s sensor allows customers to attain this visibility through ‘frictionless’ data collection.
Propeller’s website states that the sensor works with 90% of inhaled medications available on the US market.